ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global mRNA Flu Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-33A16862
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global mRNA Flu Vaccine Market Research Report 2024
BUY CHAPTERS

Global mRNA Flu Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-33A16862
Report
November 2025
Pages:176
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Moderna, Inc
BioNTech
Inovio Pharmaceuticals
Arcturus Therapeutics Holdings
Valneva
Vaxart Inc.
Entos Pharmaceuticals
Abnova Corporation
Anima Biotech
Sarepta Therapeutics
IBio Inc.
Alnylam Pharmaceuticals
Beam Therapeutics
eTheRNA immunotherapies
Barinthus Biotherapeutics

mRNA Flu Vaccine Market

The global mRNA Flu Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
mRNA Flu Vaccine leading manufacturers including Moderna, BioNTech, CureVac, Novavax, Sanofi, Inovio Pharmaceuticals, Arcturus Therapeutics Holdings, eTheRNA immunotherapies, Valneva, Vaxart, etc., dominate supply; the top five capture approximately % of global revenue, with Moderna leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global mRNA Flu Vaccine market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of mRNA Flu Vaccine Market Report

Report Metric Details
Report Name mRNA Flu Vaccine Market
Segment by Type
  • mRNA-1010
  • mRNA-1020
  • mRNA-1030
Segment by Application
  • Hospital
  • Clinic
  • Other
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Moderna, BioNTech, CureVac, Novavax, Sanofi, Inovio Pharmaceuticals, Arcturus Therapeutics Holdings, eTheRNA immunotherapies, Valneva, Vaxart, Entos Pharmaceuticals, Abnova Corporation, Anima Biotech, Sarepta Therapeutics, iBio, Barinthus Biotherapeutics, Alnylam Pharmaceuticals, Beam Therapeutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the mRNA Flu Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the mRNA Flu Vaccine Market report?

Ans: The main players in the mRNA Flu Vaccine Market are Moderna, BioNTech, CureVac, Novavax, Sanofi, Inovio Pharmaceuticals, Arcturus Therapeutics Holdings, eTheRNA immunotherapies, Valneva, Vaxart, Entos Pharmaceuticals, Abnova Corporation, Anima Biotech, Sarepta Therapeutics, iBio, Barinthus Biotherapeutics, Alnylam Pharmaceuticals, Beam Therapeutics

What are the Application segmentation covered in the mRNA Flu Vaccine Market report?

Ans: The Applications covered in the mRNA Flu Vaccine Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the mRNA Flu Vaccine Market report?

Ans: The Types covered in the mRNA Flu Vaccine Market report are mRNA-1010, mRNA-1020, mRNA-1030

1 Study Coverage
1.1 Introduction to mRNA Flu Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global mRNA Flu Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 mRNA-1010
1.2.3 mRNA-1020
1.2.4 mRNA-1030
1.3 Market Segmentation by Application
1.3.1 Global mRNA Flu Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global mRNA Flu Vaccine Revenue Estimates and Forecasts 2020-2031
2.2 Global mRNA Flu Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global mRNA Flu Vaccine Sales Estimates and Forecasts 2020-2031
2.4 Global mRNA Flu Vaccine Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global mRNA Flu Vaccine Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global mRNA Flu Vaccine Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 mRNA-1010 Market Size by Manufacturers
3.5.2 mRNA-1020 Market Size by Manufacturers
3.5.3 mRNA-1030 Market Size by Manufacturers
3.6 Global mRNA Flu Vaccine Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global mRNA Flu Vaccine Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global mRNA Flu Vaccine Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global mRNA Flu Vaccine Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global mRNA Flu Vaccine Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America mRNA Flu Vaccine Sales and Revenue by Type (2020-2031)
6.4 North America mRNA Flu Vaccine Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America mRNA Flu Vaccine Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe mRNA Flu Vaccine Sales and Revenue by Type (2020-2031)
7.4 Europe mRNA Flu Vaccine Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe mRNA Flu Vaccine Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific mRNA Flu Vaccine Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific mRNA Flu Vaccine Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific mRNA Flu Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America mRNA Flu Vaccine Sales and Revenue by Type (2020-2031)
9.4 Central and South America mRNA Flu Vaccine Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America mRNA Flu Vaccine Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa mRNA Flu Vaccine Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa mRNA Flu Vaccine Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa mRNA Flu Vaccine Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Moderna
11.1.1 Moderna Corporation Information
11.1.2 Moderna Business Overview
11.1.3 Moderna mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.1.4 Moderna mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Moderna mRNA Flu Vaccine Sales by Product in 2024
11.1.6 Moderna mRNA Flu Vaccine Sales by Application in 2024
11.1.7 Moderna mRNA Flu Vaccine Sales by Geographic Area in 2024
11.1.8 Moderna mRNA Flu Vaccine SWOT Analysis
11.1.9 Moderna Recent Developments
11.2 BioNTech
11.2.1 BioNTech Corporation Information
11.2.2 BioNTech Business Overview
11.2.3 BioNTech mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.2.4 BioNTech mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 BioNTech mRNA Flu Vaccine Sales by Product in 2024
11.2.6 BioNTech mRNA Flu Vaccine Sales by Application in 2024
11.2.7 BioNTech mRNA Flu Vaccine Sales by Geographic Area in 2024
11.2.8 BioNTech mRNA Flu Vaccine SWOT Analysis
11.2.9 BioNTech Recent Developments
11.3 CureVac
11.3.1 CureVac Corporation Information
11.3.2 CureVac Business Overview
11.3.3 CureVac mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.3.4 CureVac mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 CureVac mRNA Flu Vaccine Sales by Product in 2024
11.3.6 CureVac mRNA Flu Vaccine Sales by Application in 2024
11.3.7 CureVac mRNA Flu Vaccine Sales by Geographic Area in 2024
11.3.8 CureVac mRNA Flu Vaccine SWOT Analysis
11.3.9 CureVac Recent Developments
11.4 Novavax
11.4.1 Novavax Corporation Information
11.4.2 Novavax Business Overview
11.4.3 Novavax mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.4.4 Novavax mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Novavax mRNA Flu Vaccine Sales by Product in 2024
11.4.6 Novavax mRNA Flu Vaccine Sales by Application in 2024
11.4.7 Novavax mRNA Flu Vaccine Sales by Geographic Area in 2024
11.4.8 Novavax mRNA Flu Vaccine SWOT Analysis
11.4.9 Novavax Recent Developments
11.5 Sanofi
11.5.1 Sanofi Corporation Information
11.5.2 Sanofi Business Overview
11.5.3 Sanofi mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.5.4 Sanofi mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Sanofi mRNA Flu Vaccine Sales by Product in 2024
11.5.6 Sanofi mRNA Flu Vaccine Sales by Application in 2024
11.5.7 Sanofi mRNA Flu Vaccine Sales by Geographic Area in 2024
11.5.8 Sanofi mRNA Flu Vaccine SWOT Analysis
11.5.9 Sanofi Recent Developments
11.6 Inovio Pharmaceuticals
11.6.1 Inovio Pharmaceuticals Corporation Information
11.6.2 Inovio Pharmaceuticals Business Overview
11.6.3 Inovio Pharmaceuticals mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.6.4 Inovio Pharmaceuticals mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Inovio Pharmaceuticals Recent Developments
11.7 Arcturus Therapeutics Holdings
11.7.1 Arcturus Therapeutics Holdings Corporation Information
11.7.2 Arcturus Therapeutics Holdings Business Overview
11.7.3 Arcturus Therapeutics Holdings mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.7.4 Arcturus Therapeutics Holdings mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Arcturus Therapeutics Holdings Recent Developments
11.8 eTheRNA immunotherapies
11.8.1 eTheRNA immunotherapies Corporation Information
11.8.2 eTheRNA immunotherapies Business Overview
11.8.3 eTheRNA immunotherapies mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.8.4 eTheRNA immunotherapies mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 eTheRNA immunotherapies Recent Developments
11.9 Valneva
11.9.1 Valneva Corporation Information
11.9.2 Valneva Business Overview
11.9.3 Valneva mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.9.4 Valneva mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Valneva Recent Developments
11.10 Vaxart
11.10.1 Vaxart Corporation Information
11.10.2 Vaxart Business Overview
11.10.3 Vaxart mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.10.4 Vaxart mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Vaxart Recent Developments
11.11 Entos Pharmaceuticals
11.11.1 Entos Pharmaceuticals Corporation Information
11.11.2 Entos Pharmaceuticals Business Overview
11.11.3 Entos Pharmaceuticals mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.11.4 Entos Pharmaceuticals mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Entos Pharmaceuticals Recent Developments
11.12 Abnova Corporation
11.12.1 Abnova Corporation Corporation Information
11.12.2 Abnova Corporation Business Overview
11.12.3 Abnova Corporation mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.12.4 Abnova Corporation mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Abnova Corporation Recent Developments
11.13 Anima Biotech
11.13.1 Anima Biotech Corporation Information
11.13.2 Anima Biotech Business Overview
11.13.3 Anima Biotech mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.13.4 Anima Biotech mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Anima Biotech Recent Developments
11.14 Sarepta Therapeutics
11.14.1 Sarepta Therapeutics Corporation Information
11.14.2 Sarepta Therapeutics Business Overview
11.14.3 Sarepta Therapeutics mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.14.4 Sarepta Therapeutics mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Sarepta Therapeutics Recent Developments
11.15 iBio
11.15.1 iBio Corporation Information
11.15.2 iBio Business Overview
11.15.3 iBio mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.15.4 iBio mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 iBio Recent Developments
11.16 Barinthus Biotherapeutics
11.16.1 Barinthus Biotherapeutics Corporation Information
11.16.2 Barinthus Biotherapeutics Business Overview
11.16.3 Barinthus Biotherapeutics mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.16.4 Barinthus Biotherapeutics mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Barinthus Biotherapeutics Recent Developments
11.17 Alnylam Pharmaceuticals
11.17.1 Alnylam Pharmaceuticals Corporation Information
11.17.2 Alnylam Pharmaceuticals Business Overview
11.17.3 Alnylam Pharmaceuticals mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.17.4 Alnylam Pharmaceuticals mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 Alnylam Pharmaceuticals Recent Developments
11.18 Beam Therapeutics
11.18.1 Beam Therapeutics Corporation Information
11.18.2 Beam Therapeutics Business Overview
11.18.3 Beam Therapeutics mRNA Flu Vaccine Product Models, Descriptions and Specifications
11.18.4 Beam Therapeutics mRNA Flu Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.18.5 Beam Therapeutics Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 mRNA Flu Vaccine Industry Chain
12.2 mRNA Flu Vaccine Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 mRNA Flu Vaccine Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 mRNA Flu Vaccine Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 mRNA Flu Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global mRNA Flu Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Moderna, Inc
BioNTech
Inovio Pharmaceuticals
Arcturus Therapeutics Holdings
Valneva
Vaxart Inc.
Entos Pharmaceuticals
Abnova Corporation
Anima Biotech
Sarepta Therapeutics
IBio Inc.
Alnylam Pharmaceuticals
Beam Therapeutics
eTheRNA immunotherapies
Barinthus Biotherapeutics
List of Tables
 Table 1. Global mRNA Flu Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global mRNA Flu Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global mRNA Flu Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global mRNA Flu Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global mRNA Flu Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global mRNA Flu Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global mRNA Flu Vaccine Sales by Region (2020-2025) & (K Units)
 Table 8. Global mRNA Flu Vaccine Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global mRNA Flu Vaccine Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global mRNA Flu Vaccine Sales Share by Manufacturers (2020-2025)
 Table 12. Global mRNA Flu Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global mRNA Flu Vaccine Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global mRNA Flu Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Flu Vaccine as of 2024)
 Table 16. Global mRNA Flu Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global mRNA Flu Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers mRNA Flu Vaccine Manufacturing Base and Headquarters
 Table 19. Global mRNA Flu Vaccine Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global mRNA Flu Vaccine Sales by Type (2020-2025) & (K Units)
 Table 23. Global mRNA Flu Vaccine Sales by Type (2026-2031) & (K Units)
 Table 24. Global mRNA Flu Vaccine Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global mRNA Flu Vaccine Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global mRNA Flu Vaccine ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global mRNA Flu Vaccine Sales by Application (2020-2025) & (K Units)
 Table 29. Global mRNA Flu Vaccine Sales by Application (2026-2031) & (K Units)
 Table 30. mRNA Flu Vaccine High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global mRNA Flu Vaccine Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global mRNA Flu Vaccine Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global mRNA Flu Vaccine ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America mRNA Flu Vaccine Growth Accelerators and Market Barriers
 Table 37. North America mRNA Flu Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America mRNA Flu Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe mRNA Flu Vaccine Growth Accelerators and Market Barriers
 Table 40. Europe mRNA Flu Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe mRNA Flu Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific mRNA Flu Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific mRNA Flu Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific mRNA Flu Vaccine Growth Accelerators and Market Barriers
 Table 45. Southeast Asia mRNA Flu Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America mRNA Flu Vaccine Investment Opportunities and Key Challenges
 Table 47. Central and South America mRNA Flu Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa mRNA Flu Vaccine Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa mRNA Flu Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Moderna Corporation Information
 Table 51. Moderna Description and Major Businesses
 Table 52. Moderna Product Models, Descriptions and Specifications
 Table 53. Moderna Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Moderna Sales Value Proportion by Product in 2024
 Table 55. Moderna Sales Value Proportion by Application in 2024
 Table 56. Moderna Sales Value Proportion by Geographic Area in 2024
 Table 57. Moderna mRNA Flu Vaccine SWOT Analysis
 Table 58. Moderna Recent Developments
 Table 59. BioNTech Corporation Information
 Table 60. BioNTech Description and Major Businesses
 Table 61. BioNTech Product Models, Descriptions and Specifications
 Table 62. BioNTech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. BioNTech Sales Value Proportion by Product in 2024
 Table 64. BioNTech Sales Value Proportion by Application in 2024
 Table 65. BioNTech Sales Value Proportion by Geographic Area in 2024
 Table 66. BioNTech mRNA Flu Vaccine SWOT Analysis
 Table 67. BioNTech Recent Developments
 Table 68. CureVac Corporation Information
 Table 69. CureVac Description and Major Businesses
 Table 70. CureVac Product Models, Descriptions and Specifications
 Table 71. CureVac Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. CureVac Sales Value Proportion by Product in 2024
 Table 73. CureVac Sales Value Proportion by Application in 2024
 Table 74. CureVac Sales Value Proportion by Geographic Area in 2024
 Table 75. CureVac mRNA Flu Vaccine SWOT Analysis
 Table 76. CureVac Recent Developments
 Table 77. Novavax Corporation Information
 Table 78. Novavax Description and Major Businesses
 Table 79. Novavax Product Models, Descriptions and Specifications
 Table 80. Novavax Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. Novavax Sales Value Proportion by Product in 2024
 Table 82. Novavax Sales Value Proportion by Application in 2024
 Table 83. Novavax Sales Value Proportion by Geographic Area in 2024
 Table 84. Novavax mRNA Flu Vaccine SWOT Analysis
 Table 85. Novavax Recent Developments
 Table 86. Sanofi Corporation Information
 Table 87. Sanofi Description and Major Businesses
 Table 88. Sanofi Product Models, Descriptions and Specifications
 Table 89. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Sanofi Sales Value Proportion by Product in 2024
 Table 91. Sanofi Sales Value Proportion by Application in 2024
 Table 92. Sanofi Sales Value Proportion by Geographic Area in 2024
 Table 93. Sanofi mRNA Flu Vaccine SWOT Analysis
 Table 94. Sanofi Recent Developments
 Table 95. Inovio Pharmaceuticals Corporation Information
 Table 96. Inovio Pharmaceuticals Description and Major Businesses
 Table 97. Inovio Pharmaceuticals Product Models, Descriptions and Specifications
 Table 98. Inovio Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. Inovio Pharmaceuticals Recent Developments
 Table 100. Arcturus Therapeutics Holdings Corporation Information
 Table 101. Arcturus Therapeutics Holdings Description and Major Businesses
 Table 102. Arcturus Therapeutics Holdings Product Models, Descriptions and Specifications
 Table 103. Arcturus Therapeutics Holdings Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 104. Arcturus Therapeutics Holdings Recent Developments
 Table 105. eTheRNA immunotherapies Corporation Information
 Table 106. eTheRNA immunotherapies Description and Major Businesses
 Table 107. eTheRNA immunotherapies Product Models, Descriptions and Specifications
 Table 108. eTheRNA immunotherapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 109. eTheRNA immunotherapies Recent Developments
 Table 110. Valneva Corporation Information
 Table 111. Valneva Description and Major Businesses
 Table 112. Valneva Product Models, Descriptions and Specifications
 Table 113. Valneva Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 114. Valneva Recent Developments
 Table 115. Vaxart Corporation Information
 Table 116. Vaxart Description and Major Businesses
 Table 117. Vaxart Product Models, Descriptions and Specifications
 Table 118. Vaxart Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 119. Vaxart Recent Developments
 Table 120. Entos Pharmaceuticals Corporation Information
 Table 121. Entos Pharmaceuticals Description and Major Businesses
 Table 122. Entos Pharmaceuticals Product Models, Descriptions and Specifications
 Table 123. Entos Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 124. Entos Pharmaceuticals Recent Developments
 Table 125. Abnova Corporation Corporation Information
 Table 126. Abnova Corporation Description and Major Businesses
 Table 127. Abnova Corporation Product Models, Descriptions and Specifications
 Table 128. Abnova Corporation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 129. Abnova Corporation Recent Developments
 Table 130. Anima Biotech Corporation Information
 Table 131. Anima Biotech Description and Major Businesses
 Table 132. Anima Biotech Product Models, Descriptions and Specifications
 Table 133. Anima Biotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 134. Anima Biotech Recent Developments
 Table 135. Sarepta Therapeutics Corporation Information
 Table 136. Sarepta Therapeutics Description and Major Businesses
 Table 137. Sarepta Therapeutics Product Models, Descriptions and Specifications
 Table 138. Sarepta Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 139. Sarepta Therapeutics Recent Developments
 Table 140. iBio Corporation Information
 Table 141. iBio Description and Major Businesses
 Table 142. iBio Product Models, Descriptions and Specifications
 Table 143. iBio Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 144. iBio Recent Developments
 Table 145. Barinthus Biotherapeutics Corporation Information
 Table 146. Barinthus Biotherapeutics Description and Major Businesses
 Table 147. Barinthus Biotherapeutics Product Models, Descriptions and Specifications
 Table 148. Barinthus Biotherapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 149. Barinthus Biotherapeutics Recent Developments
 Table 150. Alnylam Pharmaceuticals Corporation Information
 Table 151. Alnylam Pharmaceuticals Description and Major Businesses
 Table 152. Alnylam Pharmaceuticals Product Models, Descriptions and Specifications
 Table 153. Alnylam Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 154. Alnylam Pharmaceuticals Recent Developments
 Table 155. Beam Therapeutics Corporation Information
 Table 156. Beam Therapeutics Description and Major Businesses
 Table 157. Beam Therapeutics Product Models, Descriptions and Specifications
 Table 158. Beam Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 159. Beam Therapeutics Recent Developments
 Table 160. Key Raw Materials Distribution
 Table 161. Raw Materials Key Suppliers
 Table 162. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 163. Milestones in Production Technology Evolution
 Table 164. Distributors List
 Table 165. Market Trends and Market Evolution
 Table 166. Market Drivers and Opportunities
 Table 167. Market Challenges, Risks, and Restraints
 Table 168. Research Programs/Design for This Report
 Table 169. Key Data Information from Secondary Sources
 Table 170. Key Data Information from Primary Sources


List of Figures
 Figure 1. mRNA Flu Vaccine Product Picture
 Figure 2. Global mRNA Flu Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. mRNA-1010 Product Picture
 Figure 4. mRNA-1020 Product Picture
 Figure 5. mRNA-1030 Product Picture
 Figure 6. Global mRNA Flu Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 7. Hospital
 Figure 8. Clinic
 Figure 9. Other
 Figure 10. mRNA Flu Vaccine Report Years Considered
 Figure 11. Global mRNA Flu Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 13. Global mRNA Flu Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global mRNA Flu Vaccine Revenue Market Share by Region (2020-2031)
 Figure 15. Global mRNA Flu Vaccine Sales (2020-2031) & (K Units)
 Figure 16. Global mRNA Flu Vaccine Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 17. Global mRNA Flu Vaccine Sales Market Share by Region (2020-2031)
 Figure 18. Top 5 and Top 10 Manufacturers mRNA Flu Vaccine Sales Volume Market Share in 2024
 Figure 19. Global mRNA Flu Vaccine Revenue Market Share Ranking (2024)
 Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 21. mRNA-1010 Revenue Market Share by Manufacturer in 2024
 Figure 22. mRNA-1020 Revenue Market Share by Manufacturer in 2024
 Figure 23. mRNA-1030 Revenue Market Share by Manufacturer in 2024
 Figure 24. Global mRNA Flu Vaccine Sales Market Share by Type (2020-2031)
 Figure 25. Global mRNA Flu Vaccine Revenue Market Share by Type (2020-2031)
 Figure 26. Global mRNA Flu Vaccine Sales Market Share by Application (2020-2031)
 Figure 27. Global mRNA Flu Vaccine Revenue Market Share by Application (2020-2031)
 Figure 28. North America mRNA Flu Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 29. North America mRNA Flu Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 30. North America Top 5 Manufacturers mRNA Flu Vaccine Sales Revenue (US$ Million) in 2024
 Figure 31. North America mRNA Flu Vaccine Sales Volume (K Units) by Type (2020- 2031)
 Figure 32. North America mRNA Flu Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 33. North America mRNA Flu Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 34. North America mRNA Flu Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 35. US mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 36. Canada mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 37. Mexico mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 38. Europe mRNA Flu Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 39. Europe mRNA Flu Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 40. Europe Top 5 Manufacturers mRNA Flu Vaccine Sales Revenue (US$ Million) in 2024
 Figure 41. Europe mRNA Flu Vaccine Sales Volume (K Units) by Type (2020-2031)
 Figure 42. Europe mRNA Flu Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 43. Europe mRNA Flu Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 44. Europe mRNA Flu Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 45. Germany mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 46. France mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 47. U.K. mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 48. Italy mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 49. Russia mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 50. Asia-Pacific mRNA Flu Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 51. Asia-Pacific mRNA Flu Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 52. Asia-Pacific Top 8 Manufacturers mRNA Flu Vaccine Sales Revenue (US$ Million) in 2024
 Figure 53. Asia-Pacific mRNA Flu Vaccine Sales Volume (K Units) by Type (2020- 2031)
 Figure 54. Asia-Pacific mRNA Flu Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 55. Asia-Pacific mRNA Flu Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 56. Asia-Pacific mRNA Flu Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 57. Indonesia mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 58. Japan mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 59. South Korea mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 60. China Taiwan mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 61. India mRNA Flu Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 62. Central and South America mRNA Flu Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 63. Central and South America mRNA Flu Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 64. Central and South America Top 5 Manufacturers mRNA Flu Vaccine Sales Revenue (US$ Million) in 2024
 Figure 65. Central and South America mRNA Flu Vaccine Sales Volume (K Units) by Type (2021-2031)
 Figure 66. Central and South America mRNA Flu Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 67. Central and South America mRNA Flu Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 68. Central and South America mRNA Flu Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 69. Brazil mRNA Flu Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 70. Argentina mRNA Flu Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 71. Middle East, and Africa mRNA Flu Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 72. Middle East and Africa mRNA Flu Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 73. Middle East and Africa Top 5 Manufacturers mRNA Flu Vaccine Sales Revenue (US$ Million) in 2024
 Figure 74. Middle East and Africa mRNA Flu Vaccine Sales Volume (K Units) by Type (2021-2031)
 Figure 75. South America mRNA Flu Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 76. Middle East and Africa mRNA Flu Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 77. Middle East and Africa mRNA Flu Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 78. GCC Countries mRNA Flu Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 79. Turkey mRNA Flu Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 80. Egypt mRNA Flu Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 81. South Africa mRNA Flu Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 82. mRNA Flu Vaccine Industry Chain Mapping
 Figure 83. Regional mRNA Flu Vaccine Manufacturing Base Distribution (%)
 Figure 84. Global mRNA Flu Vaccine Production Market Share by Region (2020-2031)
 Figure 85. mRNA Flu Vaccine Production Process
 Figure 86. Regional mRNA Flu Vaccine Production Cost Structure
 Figure 87. Channels of Distribution (Direct Vs Distribution)
 Figure 88. Bottom-up and Top-down Approaches for This Report
 Figure 89. Data Triangulation
 Figure 90. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global mRNA Vaccines and mRNA Drugs Market Research Report 2024
mRNA Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global mRNA Treatment Market Research Report 2024
mRNA Vaccines for Infectious Diseases Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Influenza Virus Vaccine H1N1 Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Animal Flu Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Poultry Viral Disease Vaccines Market Research Report 2024
Global Seasonal Vaccines Market Research Report 2024
Global Adult Vaccines Market Research Report 2024
Global mRNA Vaccine And Therapeutics Market Insights Forecast to 2030
Global mRNA Synthesis Service Market Research Report 2024
Global Influenza Virus Kits Market Research Report 2024
Global RNA Seq Market Research Report 2024
Global HIV Vaccine Market Research Report 2025
Global Inactivated Influenza Virus Vaccine Market Research Report 2025
Global Norovirus Vaccine Market Research Report 2024
Global mRNA Purification Equipment Market Research Report 2024
Global Rapid Flu Test Market Research Report 2024
Global RNA Analysis Transcriptomic Market Research Report 2024
Global Inactivated Poultry Vaccines Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions